ArticleFrontiers in pharmacology2020

Bioluminescence Imaging-Based Assessment of the Anti-Triple-Negative Breast Cancer and NF-Kappa B Pathway Inhibition Activity of Britanin.

Xinyi Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.